Artera, a company specializing in AI-powered cancer tests, has received a license from the California Department of Public Health, allowing them to offer their ArteraAI Prostate Test in California. This makes the test accessible in one of the biggest healthcare markets in the United States. The ArteraAI Prostate Test is unique in its ability to both predict the effectiveness of therapy and forecast long-term outcomes for patients with localized prostate cancer. Available starting October 10, 2024, this test provides data-driven insights to help personalize cancer treatment decisions for patients in California.
This development is significant for Artera as it expands its reach to a state with a high incidence of prostate cancer. They aim to make AI-driven precision medicine widely accessible, giving patients more information and clarity regarding their treatment options.
Artera received College of American Pathologists (CAP) accreditation in August 2024, demonstrating their dedication to quality and patient safety. This accreditation process involves rigorous evaluation of laboratory practices, ensuring the highest standard of care.
The development of the MMAI biomarker used in the ArteraAI test originated at the University of California, San Francisco (UCSF). This predictive biomarker, acknowledged in national guidelines for localized prostate cancer, can significantly influence treatment decisions, particularly for patients considering androgen deprivation therapy (ADT) along with radiation. The availability of such validated technologies is crucial for both clinicians and patients, ensuring optimal and personalized care.
Artera is a leading precision medicine company that develops AI-powered tests to personalize cancer treatment. Their ArteraAI Prostate Test, the first of its kind, offers both prognostic and predictive results for patients with localized prostate cancer. This test utilizes a unique algorithm that analyzes digital images from a patient’s biopsy and clinical data. This information helps determine the patient’s prognosis and predict the effectiveness of specific therapies. This AI technology has been validated through numerous Phase 3 randomized trials. Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is available through their laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
